Standard
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. / Nelson, Mark Jason; Amaya, Gerardo; Clumeck, Nathan; Arns da Cunha, Clovis; Jayaweera, Dushyantha; Junod, Patrice; Li, Taisheng; Tebas, Pablo; Stevens, Marita; Buelens, Annemie; Vanveggel, Simon; Boven, Katia; ECHO and THRIVE Study Groups ; Gerstoft, Jan.
In:
Journal of Antimicrobial Chemotherapy, Vol. 67, No. 8, 2012, p. 2020-8.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Nelson, MJ, Amaya, G, Clumeck, N, Arns da Cunha, C, Jayaweera, D, Junod, P, Li, T, Tebas, P, Stevens, M, Buelens, A, Vanveggel, S, Boven, K, ECHO and THRIVE Study Groups
& Gerstoft, J 2012, '
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials',
Journal of Antimicrobial Chemotherapy, vol. 67, no. 8, pp. 2020-8.
https://doi.org/10.1093/jac/dks130APA
Nelson, M. J., Amaya, G., Clumeck, N., Arns da Cunha, C., Jayaweera, D., Junod, P., Li, T., Tebas, P., Stevens, M., Buelens, A., Vanveggel, S., Boven, K., ECHO and THRIVE Study Groups
, & Gerstoft, J. (2012).
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.
Journal of Antimicrobial Chemotherapy,
67(8), 2020-8.
https://doi.org/10.1093/jac/dks130Vancouver
Nelson MJ, Amaya G, Clumeck N, Arns da Cunha C, Jayaweera D, Junod P et al.
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.
Journal of Antimicrobial Chemotherapy. 2012;67(8):2020-8.
https://doi.org/10.1093/jac/dks130Author
Nelson, Mark Jason ; Amaya, Gerardo ; Clumeck, Nathan ; Arns da Cunha, Clovis ; Jayaweera, Dushyantha ; Junod, Patrice ; Li, Taisheng ; Tebas, Pablo ; Stevens, Marita ; Buelens, Annemie ; Vanveggel, Simon ; Boven, Katia ; ECHO and THRIVE Study Groups ; Gerstoft, Jan. / Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. In: Journal of Antimicrobial Chemotherapy. 2012 ; Vol. 67, No. 8. pp. 2020-8.
Bibtex
@article{628417a6e4f8426ca658e30291945e79,
title = "Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials",
abstract = "The efficacy and hepatic safety of the non-nucleoside reverse transcriptase inhibitors rilpivirine (TMC278) and efavirenz were compared in treatment-naive, HIV-infected adults with concurrent hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection in the pooled week 48 analysis of the Phase III, double-blind, randomized ECHO (NCT00540449) and THRIVE (NCT00543725) trials.",
author = "Nelson, {Mark Jason} and Gerardo Amaya and Nathan Clumeck and {Arns da Cunha}, Clovis and Dushyantha Jayaweera and Patrice Junod and Taisheng Li and Pablo Tebas and Marita Stevens and Annemie Buelens and Simon Vanveggel and Katia Boven and Jan Gerstoft and Jan Gerstoft",
year = "2012",
doi = "10.1093/jac/dks130",
language = "English",
volume = "67",
pages = "2020--8",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "8",
}
RIS
TY - JOUR
T1 - Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials
AU - Nelson, Mark Jason
AU - Amaya, Gerardo
AU - Clumeck, Nathan
AU - Arns da Cunha, Clovis
AU - Jayaweera, Dushyantha
AU - Junod, Patrice
AU - Li, Taisheng
AU - Tebas, Pablo
AU - Stevens, Marita
AU - Buelens, Annemie
AU - Vanveggel, Simon
AU - Boven, Katia
AU - ECHO and THRIVE Study Groups
AU - Gerstoft, Jan
PY - 2012
Y1 - 2012
N2 - The efficacy and hepatic safety of the non-nucleoside reverse transcriptase inhibitors rilpivirine (TMC278) and efavirenz were compared in treatment-naive, HIV-infected adults with concurrent hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection in the pooled week 48 analysis of the Phase III, double-blind, randomized ECHO (NCT00540449) and THRIVE (NCT00543725) trials.
AB - The efficacy and hepatic safety of the non-nucleoside reverse transcriptase inhibitors rilpivirine (TMC278) and efavirenz were compared in treatment-naive, HIV-infected adults with concurrent hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection in the pooled week 48 analysis of the Phase III, double-blind, randomized ECHO (NCT00540449) and THRIVE (NCT00543725) trials.
U2 - 10.1093/jac/dks130
DO - 10.1093/jac/dks130
M3 - Journal article
C2 - 22532465
VL - 67
SP - 2020
EP - 2028
JO - Journal of Antimicrobial Chemotherapy
JF - Journal of Antimicrobial Chemotherapy
SN - 0305-7453
IS - 8
ER -
